|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
KR102948178B1
(ko)
|
2013-07-12 |
2026-04-10 |
아스텔라스 유에스 엘엘씨 |
안과적 질환을 치료하거나 예방하기 위한 방법
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
KR102399028B1
(ko)
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
이중-특이적 항원-결합 폴리펩티드
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
AU2015345321A1
(en)
|
2014-11-10 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Anti-ANG2 antibodies and methods of use
|
|
CA2963175A1
(en)
|
2014-11-10 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use in ophthalmology
|
|
AU2015345322A1
(en)
|
2014-11-10 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-PDGF-B antibodies and methods of use
|
|
SG11201702550WA
(en)
|
2014-11-10 |
2017-04-27 |
Hoffmann La Roche |
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
US20180244779A1
(en)
*
|
2015-02-06 |
2018-08-30 |
Kadmon Corporation Llc |
Immunomodulatory agents
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
BR112017020948A2
(pt)
|
2015-03-31 |
2018-07-10 |
Ildong Pharm Co., Ltd. |
composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
|
|
HUE051165T2
(hu)
|
2015-07-29 |
2021-03-01 |
Allergan Inc |
ANG-2 elleni, csak nehézláncot tartalmazó antitestek
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
EA202192290A1
(ru)
|
2015-12-16 |
2022-02-28 |
Ридженерон Фармасьютикалз, Инк. |
Композиции и способы получения белковых микрочастиц
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
EP3478718A4
(en)
*
|
2016-07-01 |
2020-07-29 |
Paracrine Therapeutics AB |
PROCEDURES AND COMPOSITIONS FOR INHIBITION OF PDGF-CC
|
|
KR20230041834A
(ko)
|
2016-08-16 |
2023-03-24 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CN109021104B
(zh)
*
|
2017-06-12 |
2022-08-12 |
上海睿智化学研究有限公司 |
一种抗人血小板衍生生长因子β受体的抗体及其应用
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
CN108586611B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
重组全人源抗破伤风毒素单克隆抗体
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
BR112021006352A2
(pt)
*
|
2018-10-05 |
2021-07-06 |
Univ Ewha Ind Collaboration |
anticorpo receptor de pdgf e uso do mesmo
|
|
PL3857237T3
(pl)
|
2019-01-16 |
2023-07-10 |
Regeneron Pharmaceuticals, Inc. |
Sposoby charakteryzowania mostka disiarczkowego
|
|
EP4378485A3
(en)
*
|
2019-03-08 |
2024-08-28 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
CN114364693A
(zh)
|
2019-05-03 |
2022-04-15 |
新加坡保健服务私人有限公司 |
代谢性疾病的治疗和预防
|
|
AU2020275406A1
(en)
|
2019-05-13 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
MA54325A
(fr)
|
2019-06-05 |
2022-05-11 |
Regeneron Pharma |
Dispositifs et procédés pour l'administration précise de doses
|
|
IL291020B2
(en)
|
2019-09-24 |
2025-04-01 |
Regeneron Pharma |
Systems and methods for use in chromatography and regeneration
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
EP4087657A1
(en)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
KR20220140551A
(ko)
*
|
2020-02-07 |
2022-10-18 |
바이오리온 테크놀러지스 비.브이. |
혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
|
|
IL300828A
(en)
|
2020-08-31 |
2023-04-01 |
Regeneron Pharma |
Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
|
|
WO2022060223A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Linxis B.V. |
Internalizing binding molecules
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
JP2024505195A
(ja)
*
|
2021-01-25 |
2024-02-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
CA3211302A1
(en)
|
2021-03-26 |
2022-09-29 |
Ross Kenyon |
Methods and systems for developing mixing protocols
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
JP2024538673A
(ja)
|
2021-10-07 |
2024-10-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨモデリング及び制御のシステム及び方法
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
US11723955B1
(en)
|
2022-05-13 |
2023-08-15 |
Allgenesis Biotherapeutics Inc. |
VEGFR fusion protein pharmaceutical composition
|
|
USD1120314S1
(en)
|
2022-11-30 |
2026-03-24 |
Regeneron Pharmaceuticals, Inc. |
Dose delivery device
|
|
CN120418653A
(zh)
|
2022-12-16 |
2025-08-01 |
里珍纳龙药品有限公司 |
评估色谱柱完整性的方法和系统
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN118440214B
(zh)
*
|
2024-04-02 |
2025-01-28 |
山东大学 |
一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
CN118638237B
(zh)
*
|
2024-07-16 |
2025-02-28 |
山东大学 |
一种靶向人PDGFRβ的单链抗体及其在CAR-T免疫治疗中的应用
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|